0000950170-24-090329.txt : 20240805 0000950170-24-090329.hdr.sgml : 20240805 20240805073520 ACCESSION NUMBER: 0000950170-24-090329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240801 FILED AS OF DATE: 20240805 DATE AS OF CHANGE: 20240805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hughes Eric A CENTRAL INDEX KEY: 0001938678 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 241173112 MAIL ADDRESS: STREET 1: C/O TEVA STREET 2: 5 BASEL STREET, P.O. BOX 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 4951033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 BUSINESS PHONE: 972 (3) 914-8213 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 4 1 ownership.xml 4 X0508 4 2024-08-01 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001938678 Hughes Eric A C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false See "Remarks" true Ordinary Shares 2024-08-01 4 M false 52742 A 69597 D Ordinary Shares 2024-08-01 4 S false 24537 17.2507 D 45060 D Restricted Share Units 2024-08-01 4 M false 52742 0 D Ordinary Shares 52742 105486 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.2502 to $17.2550, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on August 1, 2022, with 52,742 vested on each of August 1, 2023 and August 1, 2024, 52,742 vesting on August 1, 2025, and 52,744 vesting on August 1, 2026. Executive Vice President, Global R&D and Chief Medical Officer /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes 2024-08-05